Inmod is an Israeli company that specializes in minimally invasive aesthetic devices. Think of liposuction, laser, facelifting, body contouring, and dry eye procedures. They also have patents being filed for Erectile Dysfunction for men and vaginal devices for women. Besides, with everyone talking about ozempic, we all know what happens to your skin when you lose weight drastically.
It is down 40% in a week upon lowering its revenue targets for the 3rd Quarter, which would still be a 15% YTY growth.
You might say, ha it is based in Israel; there is a war there. Well, the CEO released a statement that their distribution center is far from being affected, and only 1% of all their revenue comes from Israel. They operate mainly from their headquarters in the US. Safe, but still may be worrisome.
Inmod last 5 years in numbers:
Current Price: 21$
-Revenue growth by 45%
-EPS growth by 33%
-Operating Cash flow growth by 43%
-Equity growth by 47%
-Debt/Equity 0.40
Now with all of that mentioned, why is the stock being beaten down? It is almost 40% down YTD and ~80% from its all-time high of 90$ a share. Is it normal for a company to be severely punished upon adjusting its revenue growth given the current economic environment? Am I missing something?
Leave a Reply